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ABSTRACT 
The concept of vaccination has been around for 
centuries .Vaccines constitutes cost-effective measures for 
preventing disease. Advances in biotechnology and an 
understanding of the inductive and effector components of 
immune responses have ushered in a „golden age‟ of 
vaccine development and implementation. Many licensed 
vaccines have one or more ideal characteristics, but none 
manifests them all. Of the generic vaccine technologies and 
vaccination strategies in different stages of development, 
some have already demonstrated their flexibility, 
practicality, robustness and potential simplicity of 
production and others hold promise for the future. 
Although conventional methods of development of 
vaccines are successful in many cases, this approach took a 
long time to provide vaccines against those pathogens for 
which the solution was easy and failed to provide a solution 
for those bacteria and parasites that did not have obvious 
immunodominant protective antigens. The reverse 
approach to vaccine development takes advantage of the 
genome sequence of the pathogen. This approach allows 
not only the identification of all the antigens seen by the 
conventional methods, but also the discovery of novel 
antigens that work on a totally different paradigm. With the 
genome sequences of many bacteria, parasites and viruses 
to be completed in the near future, many vaccines 
impossible to develop will become reality, and novel 
vaccines, using non-conventional antigens (i.e. non-
structural proteins) can be developed. 
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INTRODUCTION 
Vaccines constitute cost-effective measures for preventing 
disease. Epidemiologically targeted implementation of 
vaccines has diminished morbidity and mortality from 
infectious diseases that previously were scourges and 
economic burdens (such as measles, polio, diphtheria, 
invasive Haemophilus influenzae type b and pneumococcal 
infections). Advances in biotechnology and an 
understanding of the inductive and effector components of 
immune responses have ushered in a „golden age‟ of 
vaccine development and implementation.1 .This is a 
propitious moment to examine the landscape of vaccine 
development and immunization from a global perspective 
and to consider how burgeoning immunological knowledge 
and biotechnological advances are being harnessed. This 
commentary on preventive vaccines against infectious 
agents identifies the desirable characteristics a vaccine 
should have and discusses strategies to achieve them and 
the role of Reverse Vaccinology in the vaccine 
development. 
A Brief History of Vaccination: 
The concept of vaccination has been around for centuries. 
One of the first documented accounts of immunization was 
practiced by the ancient Chinese around AD 1000, by 
inhaling dried powders derived from the crusts of smallpox 
lesions 2. Around the 15th century, a practice of applying 
powdered smallpox “crusts” and inserting them with a pin 
or “poking” device into the skin became commonplace. 
The process was referred to as Variolation and became 
quite common in the Middle East. Oddly, these practices 
were not meant to save lives but to preserve the beauty of 
young women. Variolation was brought to the West by a 
tenacious aristocrat, Lady Mary Montague, who played a 
critical role in promoting the process in Great Britain, 
despite a great deal of resistance from the medical 
establishment, both because Variolation was considered an 
“Oriental” process and because of her gender 3.  These 
initial empirical observations gave rise to the origin of 
vaccination. Immunization, derived from the Latin word 
immunis meaning “free of,” was investigated by the well- 
known physician Edward Jenner in the late 18th century. 
Jenner (1796) created the first successful vaccine against 
smallpox after showing that infectious material from a 
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woman with cowpox, when inoculated into the arm of a 
young boy, could prevent the young boy from acquiring the 
life- threatening virus 4. Smallpox was the first disease 
scientists tried to prevent by intentionally inoculating 
individuals at risk with the infecting agent5. Almost a 
century later, Louis Pasteur (1885), a world- renowned 
French chemist and biologist, also considered the “father of 
immunology,” became involved in the practice of 
immunization, and became known for his principles of 
“isolate, inactivate, and inject” 6. Pasteur is particularly 
renowned for his work on the vaccine for anthrax (a 
bacterial infection that was decimating sheep herds at the 
time) and rabies (a highly contagious viral infection that 
attacks the central nervous system). Pasteur was able to 
produce an attenuated form of the virus, which he then used 
for immunization7. A vaccine is comprised of antigens 
(molecules that trigger an immune response) that 
artificially induce the body to resist infection by stimulating 
the body‟s immune system (white cells) into producing 
specialized proteins known as antibodies. There are 
different types of vaccines which are currently available. 
(Table 1) Vaccines may be monovalent (single 
components) or multivalent (multiple components). A 
monovalent vaccine is designed to immunize against a 
single antigen or single microorganism. A multivalent or 
polyvalent vaccine is designed to immunize against two or 
more strains of the same microorganism, or against two or 
more microorganisms. 8 
 
 
Table 1 Several Vaccine Types Are Currently Used to Induce an Immune Response against the Following Organisms 
Sl.no Vaccine Type Examples 
1 Live, attenuated vaccines TB,Yellow Fever, Polio, Measles, Mumps, Rubella, Varicella zoster 
virus 
2 Inactivated vaccines/killed Infl uenza, Cholera, HAV (hepatitis A Virus),  rabies, and hepatitis B, 
Pertussis 
3 Subunit vaccines HPV( human papillomavirus), Adenovirus,Salmonella 
4 Toxoid vaccines Tetanus, Diptheria 
5 Conjugate vaccine S. Pneumoniae and Haemophilus influenza 
6 DNA vaccines bird flu DNA vaccine 
7 Recombinant vector vaccines Hepatitis B virus 
8 Combination vaccines DPT (Diphtheria, Pertussis and Tetanus) 
 
Characteristics of ideal vaccines 
Many licensed vaccines have one or more ideal 
characteristics, but none manifests them all. Although 
vaccine safety is an issue worldwide, this concern is 
particularly conspicuous in industrialized countries where 
the very success of vaccines has led the public to forget the 
dangers of previously common infectious diseases and 
instead to dwell on rare adverse events attributed to 
vaccines. Some adverse events are indeed vaccine 
associated, whereas for others there is no valid basis for 
„incriminating‟ vaccines. The challenge faced in 
developing new vaccines is to achieve strong 
immunogenicity without increasing „reactogenicity‟. In 
developing countries, where infectious diseases morbidity 
and mortality burden remains high, a different risk-benefit 
ratio prevails. In such venues, generally mild untoward 
effects and serious but rare adverse events attributable to 
vaccines (such as vaccine-associated paralytic 
poliomyelitis) are considered an acceptable price for the 
prevention of death and debilitating disease for the masses. 
Another chief consideration for vaccines is that they confer 
long-lived efficacy, an important determinant of cost-
effectiveness after implementation. Some wild-type 
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infections (measles) and vaccines (17D yellow fever) 
confer enduring, even lifelong, immunity after a single 
immunizing event. Key to the development of vaccines that 
elicit enduring protection is the induction of strong, long-
lived immunological T and B cell memory to antigens that 
correlate with protection; that is, the ability to „recall‟ 
previous exposures to antigen and to mount enhanced, 
accelerated effector responses.9,  
Research in nonhuman primates and in humans using new 
immunological and flow cytometry techniques is 
identifying the cells responsible for maintaining T and B 
cell memory and long-lived protection after vaccination. 
Future measurements of the specificity, subsets, magnitude 
and longevity of T and B memory responses elicited by 
immunization may guide vaccine development by 
providing immunological correlates of long-lived 
protection before epidemiological data become available. 
Current vaccine development technologies and 
strategies  
Of the generic vaccine technologies and vaccination 
strategies in different stages of development, some have 
already demonstrated their flexibility, practicality, 
robustness and potential simplicity of production and others 
hold promise for the future. They are as follow  
 Conjugate vaccines 
 Rational attenuation of known pathogens by 
inactivation of specific genes 
 Bacterial live vector vaccines 
 Viral live vector vaccines 
 Subunit vaccines 
 „Reverse vaccinology‟ (genomics-based vaccines) 
 Nonliving antigen delivery systems (such as 
liposomes, proteosomes, virus-like particles, 
virosomes and microspheres) 
 DNA vaccines and replicons 
 „Heterologous‟ prime-boost vaccination strategies 
 Powerful but well tolerated adjuvants to enhance 
immune responses to vaccines 
 Needle-free administration of vaccines 
These strategies address the desired characteristics of an 
ideal vaccine in various ways (Table 1.2).10, 
Attributes Conjugat
e 
vaccines 
Attenuat
ed live 
Vaccines 
Bacteri
al live 
vector 
Vaccine
s 
Viral 
live 
Vaccine
s vector  
Subunit 
Vaccine
s  
Genomi
c based 
vaccine
s  
Nonlivin
g 
antigen 
delivery 
systems 
DNA 
Vaccine
s and 
replico
ns 
‘Heterologo
us’ 
Prime boost 
stratergies 
New 
adjuvant
s 
General clinical 
tolerability 
High High High High High High High High High Moderat
e 
Potential 
transmissibility to 
non-target subjects 
No Yes Yes Yes No No No No Yes (if live 
vector 
Vaccines 
used) 
no 
Safety concerns for 
immunocompromis
ed Subjects 
No Yes Yes Yes No No No No Yes (if live 
vector 
Vaccines 
used) 
no 
Likelihood of a 
single dose 
immunization 
regimen 
Low High Modera
te 
Modera
te 
Low Low Modera
te 
 
Low No Moderat
e 
 
Expected immunogenicity: 
Antibodies High High High High Modera
te 
High High Modera
te 
High High 
TH1 cytokine 
responses 
Low High High High Low Low/M
oderate 
Modera
te 
Modera
te 
High High 
CTL None High High High Low Low Modera
te 
Modera
te 
High High 
Potential for needle-free administration: 
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Mucosal Low High High High Low Low High Modera
te 
High Moderat
e 
Transcutaneous Medium Lowa Lowa High High High High High Moderate Moderat
e 
Needle-free 
injection devices 
High Moderat
ea 
Lowa High High High High High High High 
 
aPossible for live viral vaccines that are well tolerated when administered parenterally. Many bacterial vaccines (such as S. Typhi 
live vectors) are likely to be reactogenic when administered this way. TH1, T helper type 1; CTL, cytotoxic T lymphocyte. 
 
Conventional Vaccinology Vs Reverse Vaccinology 
11
 
The conventional approach to vaccine development uses 
two methods: first, attenuation of pathogens by serial 
passages in vitro to obtain live-attenuated strains to be used 
as vaccines, and second, identification of protective 
antigens to be used in non-living, subunit vaccines. In order 
to identify the components of the pathogen suitable for 
vaccine development, the pathogen is grown in laboratory 
conditions and the components building the pathogen are 
first identified one at a time, by biochemical, serological or 
genetic methods. 
The identification of protective antigens that could be 
potential vaccine candidates involves separating each 
component of the pathogen one by one. This approach is 
time-consuming, can take years or decades and allows the 
identification only of those antigens that can be purified in 
quantities suitable for vaccine testing. For the bacterial and 
parasitic pathogens studied to date, the maximum number 
of potential vaccine antigens identified during a century of 
vaccine development is usually less than ten. Although 
successful in many cases, this approach took a long time to 
provide vaccines against those pathogens for which the 
solution was easy and failed to provide a solution for those 
bacteria and parasites that did not have obvious 
immunodominant protective antigens. 
Reverse vaccinology 
The reverse approach to vaccine development takes 
advantage of the genome sequence of the pathogen. The 
genome sequence provides at once a catalog of virtually all 
protein antigens that the pathogen can express at any time. 
As shown in Figure 1, this approach starts from the 
genomic sequence and, by computer analysis, predicts 
those antigens that are most likely to be vaccine candidates. 
The approach can, therefore, be very naïve, and poses the 
question of whether any of the potential antigen candidates 
can provide protective immunity without knowing whether 
the antigen is abundant, immunogenic during infection or 
expressed in vitro. This approach allows not only the 
identification of all the antigens seen by the conventional 
methods, but also the discovery of novel antigens that work 
on a totally different paradigm. Therefore, this method 
allows the discovery of novel mechanisms of immune 
intervention. The feasibility of the approach relies heavily 
on the availability of a high-throughput system to screen 
protective immunity. When this is available, in theory all 
genes of a pathogen can be tested, without any bias of any 
type. Unfortunately, owing to our limited knowledge of 
vaccine immunology, good correlates of protection are rare 
and, therefore, screening for protective immunity is the 
rate-limiting step of reverse vaccinology. The other limit of 
this approach is the inability to identify non-protein 
antigens such as polysaccharides, which are important 
components of many successful vaccines, and the 
identification of CD1-restricted antigens such as 
glycolipids, which represent new promising vaccine 
candidates. 
Potential applications of reverse vaccinology 
The publication of the complete genome sequence of many 
bacteria, parasites and viruses means that the reverse 
approach to vaccine development can be put into practice. 
Below we discuss the different approaches that are being 
used or potentially could be used to develop novel and 
effective vaccines against a variety of pathogens. 
Group B meningococcus 
Group B meningococcus (MenB) represents the first 
example of the successful application of reverse 
vaccinology. The conventional approach to vaccine 
development against this pathogen had been struggling for 
four decades without progress. Using reverse vaccinology, 
fragments of DNA were screened by computer analysis 
while the MenB nucleotide genome sequence was being 
determined. Six hundred novel genes were predicted to 
code for surface-exposed or exported proteins. These were 
cloned and expressed in Escherichia coli as fusions to the 
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glutathione transferase or to a histidine tag. Of these fusion 
proteins, 350 were successfully expressed, purified and 
used to immunize mice. The sera obtained were used to 
confirm the surface exposure of the proteins by ELISA and 
FACS analysis, and to test for the ability to induce 
complement-mediated in vitro killing of bacteria, a test that 
correlates with vaccine efficacy in humans. Within 18 
months, while the nucleotide sequence was still being 
finalized, 85 novel surface-exposed proteins were 
discovered and 25 of these were shown to induce 
bactericidal antibodies. These numbers are impressive if 
one considers that during the past four decades no more 
than a dozen of such proteins had been identified. The 
surprising finding was not only the high number of the new 
proteins found but also the quality of the new proteins. In 
addition to the conventional outer membrane proteins with 
variable surface-exposed loops , many of the new proteins 
were lipoproteins or other types of surface-associated 
proteins without membrane-spanning domains . These were 
often conserved in sequence, and carried multiple 
protective epitopes conserved in most strains. These novel 
proteins provide an optimal basis for the development of a 
novel and effective vaccine against MenB. 
Malaria 
Malaria, together with AIDS and tuberculosis, belongs to 
the triad of the most dangerous diseases that threaten 
human health. The 500 million new infections each year 
and 2.5 million annual deaths indicate that all measures 
used so far to control the disease have failed. Vaccination 
would be an effective way to control the spread of malaria, 
but vaccines are not available, despite many years of 
research. Approximately 20 antigens have been identified 
from the malaria parasite but none of them is good enough 
for a vaccine. The problem is further complicated by the 
different antigenic profiles expressed by sporozoites, 
merozoites and gametocytes that the parasite assumes 
during its life cycle. The solution can only come from a 
genomic approach. The sequence of two of the 14 
chromosomes of Plasmodium falciparum have been 
published and provided the full set of genes contained in 
the two chromosomes. The complete sequence of the whole 
genome will soon provide information on the predicted 
6000 genes. Analysis of the whole genome expression will 
show which genes are expressed by the sporozoite, liver 
and sexual life-stages of the parasite. Expression of genes 
predicted to be immunogenic as recombinant proteins 
delivered with adjuvants or as DNA vaccines will 
eventually provide the effective vaccine against malaria. 
The task is a formidable challenge, however, it is doable. It 
is just a matter of resources and co-ordination. The most 
difficult task is the development of an in vivo or in vitro 
model that allows high-throughput screening of vaccine 
candidates. 
Tuberculosis 
Mycobacterium tuberculosis infects approximately two 
billion people worldwide and causes 1.5 million deaths 
annually. The inability of AIDS patients to keep the 
infection under control and the appearance of multi-
resistant strains make the disease an unrestrained danger. 
The available live-attenuated BCG vaccine is not a 
solution, because of the variable efficacy reported in the 
trials. Furthermore, subunit vaccines have not been 
developed because all the antigens identified by 
conventional vaccinology provide protection that in animal 
models is lower than that provided by BCG. Also vaccine 
development and testing is complicated by the long time 
required for bacterial growth. 
The sequence of the whole genome of M. tuberculosis  has 
provided a list of all possible genes, which now can all be 
expressed as recombinant proteins or as DNA vaccines and 
tested for protective immunity . The absence of a high-
throughput screening for protective antigens makes the 
effort difficult but doable by means of a systematic 
approach. However, a number of genome- and proteome 
based approaches are providing novel vaccine candidates, 
while at the same time the increased knowledge of this 
difficult bacterium makes it easier to approach. 
The combination of the genome and the use of the fast 
growing Mycobacterium marinum is the winning 
combination to accelerate the discovery of an effective 
tuberculosis vaccine .  
Syphilis 
During the past four centuries, syphilis has been a 
nightmare comparable to today‟s AIDS. If untreated, this 
sexually-transmitted disease leads to neurological 
disorders, cardiovascular problems and death, but after the 
discovery of penicillin the disease became easy to control. 
However, today syphilis represents a new threat both in 
developed and developing countries because it causes 
genital ulcers, which facilitate the spread of HIV. Syphilis 
is caused by a bacterium, Treponema pallidum, which 
cannot be cultivated in the laboratory and, therefore, has 
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been refractory to conventional approaches to vaccine 
development. Attempts to identify vaccine antigens using 
the bacterium grown in rabbits had identified 
approximately 20 different antigens. Once again, the 
sequence of the complete genome made available at once 
all the genes of the bacterium, which can all be expressed 
as recombinant proteins or as DNA vaccines. Therefore, for 
the first time it is now possible to approach development of 
a syphilis vaccine in a systematic way. The absence of a 
high-throughput animal model again makes the problem 
difficult but not impossible to solve. 
Hepatitis C virus 
Hepatitis C virus (HCV) is perhaps the best example of a 
vaccine being developed entirely by reverse vaccinology. 
In this case the virus that causes the disease has never been 
cultivated in vitro (it grows only in humans and 
chimpanzees and has never been visualized by electron 
microscopy, making it impossible to use any conventional 
approach to vaccine development. The cloning and 
sequencing of the HCV genome allowed the identification 
of the etiological agent , the recombinant expression of its 
proteins, and the immediate development of diagnostic 
tools, which prevents hundreds of new infections each day 
ever since. The availability of the genome sequence also 
allowed the prediction of the envelope proteins that 
normally are used to develop vaccines against enveloped 
viruses. These proteins (E1 and E2) have been expressed in 
many hosts, but so far only mammalian cells have been 
able to express them in a form that induces production of 
antibodies able to interfere with the binding of E2 to the 
host receptor. These recombinant proteins have been able 
to protect chimpanzees from infection with the homologous 
HCV virus. While vaccine development using the E1 and 
E2 conventional vaccine targets is making progress, 
perhaps the most interesting questions are whether we can 
take advantage of the knowledge of the genome to design 
totally non-conventional vaccine targets and whether 
proteins never used in conventional vaccines (i.e. non-
structural proteins) can become effective vaccines. 
These proteins should be able to confer protection mostly 
through cell-mediated immunity and not rely on antibody 
neutralization of viral infection. The encouraging results 
obtained with some early proteins such as Tat and Rev in 
the case of HIV suggest that this may be a novel way to 
protect against viruses. 
 
Other pathogens 
The pathogens described above are perhaps some of the 
most representative among those that can be approached by 
reverse vaccinology. However, the list of the pathogens 
where the conventional approaches to vaccine development 
have failed or provided only partial solutions is extensive. 
Among these we can list bacteria such as Chlamydia, 
pneumococcus , Streptococcus, Staphylococcus, 
pseudomonas, Borrelia , Escherichia coli, gonococcus, 
typhoid, Brucella, Ricksettia and Bartonella (the genome 
sequences of most of these pathogens are about to be 
completed and available on the website 
http://www.tigr.org), and parasites such as Leishmania and 
many others. 
Conclusions 
Conventional approaches to vaccine development are time 
consuming, identify only abundant antigens that may or 
may not provide immunity, and fail when the pathogen 
cannot be cultivated under laboratory conditions. Reverse 
vaccinology (i.e. genomic-based approaches to vaccine 
development) can overcome these problems and allow 
researchers to identify novel antigen vaccine candidates. 
The sequencing of the complete genome of many 
pathogens, such as group B meningococcus, has allowed 
the successful application of reverse vaccinology where 
conventional approaches have failed. With the genome 
sequences of many other bacteria, parasites and viruses to 
be completed in the near future, reverse vaccinology means 
that many vaccines that were impossible to develop will 
become reality, and novel vaccines, using non-conventional 
antigens (i.e. non-structural proteins) can be developed. 
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